SEC EDGARJun 25$ONC

Wang Lai sold $296K of ONC

Wang Lai (President, Global Head of R&D) sold 1,068 shares of BeOne Medicines Ltd. (ONC) at $276.74 ($0.30M total) on 2026-06-23.

Original reporting

SEC EDGAR · Wang Lai

Published Jun 25, 2026, 9:14 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 25, 2026, 9:20 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ONC

Neutral

medium confidence

Mentioned

$ONC

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ONCNeutralLow

Why it matters

The newest concrete fact is the reported open-market sale by an R&D executive, leaving the insider with 0 shares. It may slightly influence sentiment but does not introduce new operational or financial information about ONC.

Market read

Traders may monitor for follow-on insider activity, but this single sale without a stated catalyst is unlikely to drive a durable repricing.

What to watch

Insider sales often have non-informational drivers (taxes, estate planning, exercise/holdings changes). The filing doesn’t state reasons, and the share count is small relative to typical trading liquidity.

Relevance 4/10Novelty 3/10Timing: after-hours/filing day (2026-06-25) for a 2026-06-23 sale

Background

This is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ONCNeutralMedium confidence

Context

Form 4 shows Wang Lai (President, Global Head of R&D) sold 1,068 ONC shares for about $295.6K on 2026-06-23.

Expected impact

Likely limited near-term impact; any effect would be small and sentiment-driven.

Evidence & confidence

The filing is a disclosed sale with no 10b5-1 plan and no accompanying company-specific news (no guidance, trial, deal, or enforcement). Size is modest versus typical market moves, so impact is usually muted.

Market effects

Sector

No clear sector read-through; this is company-specific insider trading disclosure.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

The sale could be for diversification, taxes, or pre-planned liquidity needs; absence of a 10b5-1 plan doesn’t automatically imply negative fundamentals.

Key entities

issuer
BeOne Medicines Ltd.
Subject of the Form 4 insider transaction; ticker ONC.
insider
Wang Lai
President, Global Head of R&D; sold 1,068 shares on 2026-06-23.

Read at source ← All news

$ONCMed

BeOne Medicines Ltd (ONC) Q3 2026 Earnings Call Highlights: Brukinsa Tops $1 Billion

BeOne Medicines reported Q3 2026 earnings, highlighting Brukinsa's U.S. sales exceeding $1 billion. Management discussed competitive threats, R&D investments, and clinical trial updates. Operating margins are expected to expand by over 10% in 2026, with future growth balanced against investment. The company is expanding its CDK4 inhibitor Phase III study and partnering with Revolution Medicines on precision oncology initiatives.

finance.yahoo.comNov 5

$ONCHighAI 8/10

Jefferies raises BeOne Medicines stock price target on solid quarter

Jefferies raised its price target for BeOne Medicines (ONC) to $470 from $410, citing strong quarterly results and raised guidance. The stock trades near its 52-week high at $387.27. The company reported $1.7B in Q2 2026 revenue, up 29% YoY, and raised its full-year 2026 revenue guidance to $6.6B-$6.8B. Analysts highlight robust margins, revenue growth, and a solid pipeline.

investing.comNov 5

$ONCHigh

BeOne Medicines DRC earnings beat by $2.66, revenue topped estimates

BeOne Medicines DRC (ONC) reported Q3 EPS of $4.55, exceeding estimates by $2.66, with revenue of $1.89B, topping expectations of $1.75B. The stock is up 8.47% over 3 months and 19.10% over 12 months. InvestingPro rates its financial health as 'great performance'.

investing.comNov 5

$ONCHighAI 8/10

BeOne Medicines Q3 Revenue Rises 34% to $1.9 Billion; Raises 2026 Outlook

BeOne Medicines reported Q3 2026 revenue of $1.89 billion, up 34% YoY, with GAAP earnings of $3.28 per ADS. The company raised its full-year revenue guidance to $6.9B-$7.0B. Key products BRUKINSA and TEVIMBRA saw regulatory progress, and the company announced new collaborations and partnerships.

tradingview.comNov 5

$ONCHighAI 9/10

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year • BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,

SEC EDGAR 8-KNov 5